Surmodics (SRDX) Competitors

AtriCure (NASDAQ:ATRC) and Surmodics (NASDAQ:SRDX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, community ranking, earnings and institutional ownership.

Which has more risk & volatility, ATRC or SRDX?

AtriCure has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, Surmodics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.

Is ATRC or SRDX more profitable?

AtriCure has a net margin of -9.61% compared to Surmodics' net margin of -11.48%. Surmodics' return on equity of -4.39% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	-9.61%	-6.80%	-5.19%
Surmodics	-11.48%	-4.39%	-2.95%

Does the media favor ATRC or SRDX?

In the previous week, AtriCure had 1 more articles in the media than Surmodics. MarketBeat recorded 7 mentions for AtriCure and 6 mentions for Surmodics. AtriCure's average media sentiment score of 0.98 beat Surmodics' score of 0.58 indicating that AtriCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Surmodics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders have more ownership in ATRC or SRDX?

99.1% of AtriCure shares are owned by institutional investors. Comparatively, 96.6% of Surmodics shares are owned by institutional investors. 3.2% of AtriCure shares are owned by insiders. Comparatively, 8.9% of Surmodics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Does the MarketBeat Community favor ATRC or SRDX?

AtriCure received 232 more outperform votes than Surmodics when rated by MarketBeat users. Likewise, 69.51% of users gave AtriCure an outperform vote while only 62.36% of users gave Surmodics an outperform vote.

Company	Underperform	Outperform
AtriCure	Outperform Votes 570 69.51%	Underperform Votes 250 30.49%
Surmodics	Outperform Votes 338 62.36%	Underperform Votes 204 37.64%

Which has stronger valuation & earnings, ATRC or SRDX?

Surmodics has lower revenue, but higher earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$465.31M	3.66	-$44.70M	-$0.95	-36.68
Surmodics	$125.45M	3.52	-$11.54M	-$1.01	-30.60

Do analysts rate ATRC or SRDX?

AtriCure currently has a consensus price target of $51.56, suggesting a potential upside of 47.94%. Surmodics has a consensus price target of $50.00, suggesting a potential upside of 61.76%. Given Surmodics' higher probable upside, analysts plainly believe Surmodics is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
Surmodics	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

AtriCure beats Surmodics on 12 of the 18 factors compared between the two stocks.